2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 08:54, 18 December 2023
, 18 December 2023→Bioavailability of NMN
| Line 114: | Line 114: | ||
|+ | |+ | ||
! | ! | ||
! rowspan="3" |After | |||
! colspan="2" |NMN Group | ! colspan="2" |NMN Group | ||
! colspan="2" |Placebo Group | ! colspan="2" |Placebo Group | ||
| Line 131: | Line 132: | ||
|- | |- | ||
|Whole blood, 250 mg/day{{pmid|35927255}} | |Whole blood, 250 mg/day{{pmid|35927255}} | ||
|12 weeks | |||
|0.176±0.063 | |0.176±0.063 | ||
|1.07±0.16 | |1.07±0.16 | ||
| Line 137: | Line 139: | ||
|3.51±1.86 | |3.51±1.86 | ||
|- | |- | ||
| | |||
| | | | ||
| | | | ||
| Line 144: | Line 147: | ||
| | | | ||
|- | |- | ||
| | |||
| | | | ||
| | | | ||